RecruitingFemale onlyEN originalBreast cancerHormone receptor positive (HR+)

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

To observe and evaluate the clinical efficacy and safety of continuous use of OFS for premenopausal patients with early breast cancer after 5 years use of OFS. This study is a multicenter, prospective, observational, non randomized controlled, open-label real world study based on hospital medical record system data, aimed at evaluating the benefits of continuing to use OFS after 5 years of use. The retrospective analysis plan includes patient data from September 1, 2023 to September 1, 2026. Join two cohorts: the continued use group and the discontinued use group after 5 years of OFS, respectively.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Diagnoza wczesnego pierwotnego raka piersi
  • Kobieta w wieku 18-60 lat
  • Dodatni receptory hormonalne, ujemny HER2
  • Otrzymywanie leczenia hamującego jajniki przez 5 lat
  • Ogólny stan zdrowia pozwalający na uczestnictwo (ECOG 0-1)
  • Dobrowolna zgoda na uczestnictwo w badaniu

✗ Disqualifies

  • Przerzuty do mózgu z objawami (ból głowy, obrzęk, zaburzenia widzenia)
  • Przerzuty do innych narządów z objawami
  • Stosowanie innego leczenia wpływającego na hamowanie jajników
  • Leczenie hamujące jajniki trwające krócej niż 5 lat

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Maximum age
60 Years
Last updated (source)
March 17, 2025
Sex
Female only

Therapies / drugs in trial

Locations (1)

Wu Xinhong

Wuhan, China

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.